MedTrace Logo

Letrozole in Uterine Leiomyosarcoma

NCT05649956 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-31

No results posted yet for this study

Summary

This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.

Conditions

  • Uterine Leiomyosarcoma

Interventions

DRUG

Letrozole

Letrozole 2.5 mg PO daily

Sponsors & Collaborators

  • GOG Foundation

    lead NETWORK

Principal Investigators

  • Bradley Corr, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-17
Primary Completion
2028-07-30
Completion
2029-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05649956 on ClinicalTrials.gov